{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:22:04Z","timestamp":1777328524326,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.metabol.2012.04.013","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:07:59Z","timestamp":1340755679000},"page":"1331-1336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials"],"prefix":"10.1016","volume":"61","author":[{"given":"Joo-Pin","family":"Foo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.metabol.2012.04.013_bb0005","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"9377","key":"10.1016\/j.metabol.2012.04.013_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study","volume":"362","author":"Mocroft","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.metabol.2012.04.013_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/sti.79.2.137","article-title":"A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals","volume":"79","author":"Power","year":"2003","journal-title":"Sex Transm Infect"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0020","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0025","first-page":"1423","article-title":"The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B","volume":"76","author":"Feingold","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.metabol.2010.09.011","article-title":"Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"issue":"9170","key":"10.1016\/j.metabol.2012.04.013_bb0035","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/QAI.0b013e31804216cf","article-title":"Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy","volume":"44","author":"Shlay","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/QAI.0b013e318074ef83","article-title":"HIV and metabolic syndrome: a comparison with the general population","volume":"45","author":"Bonfanti","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0050","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.metabol.2010.08.007","article-title":"Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood","volume":"60","author":"Dimock","year":"2011","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.metabol.2012.04.013_bb0060","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"issue":"55","key":"10.1016\/j.metabol.2012.04.013_bb0065","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2002-021704","article-title":"Clinical review 159: human immunodeficiency virus\/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies","volume":"88","author":"Leow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0070","first-page":"518","article-title":"Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome","volume":"17","author":"Sellmeyer","year":"1996","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.metabol.2012.04.013_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0924-8579(03)00115-8","article-title":"Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management","volume":"22","author":"Calza","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.metabol.2012.04.013_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0002-9343(91)80154-E","article-title":"Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome","volume":"90","author":"Grunfeld","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2012.04.013_bb0085","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ajhp\/55.3.233","article-title":"Protease inhibitors for the treatment of human immunodeficiency virus infection","volume":"55","author":"Kakuda","year":"1998","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0095","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0959-437X(95)80025-5","article-title":"Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma","volume":"5","author":"Tontonoz","year":"1995","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"10.1016\/j.metabol.2012.04.013_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/003655400750045196","article-title":"Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment","volume":"32","author":"Penzak","year":"2000","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"10.1016\/j.metabol.2012.04.013_bb0105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-130-8-199904200-00014","article-title":"The role of leptin in human obesity and disease: a review of current evidence","volume":"130","author":"Mantzoros","year":"1999","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0110","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1210\/jcem.86.5.7463","article-title":"Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia","volume":"86","author":"Weyer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/367859","article-title":"Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin","volume":"36","author":"Nagy","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.metabol.2012.04.013_bb0120","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2002-020795","article-title":"Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy","volume":"88","author":"Addy","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2012.04.013_bb0125","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.metabol.2011.03.009","article-title":"Plasma adiponectin\u2014an independent indicator of liver fat accumulation","volume":"60","author":"Pisto","year":"2011","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2012.04.013_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2011.06.021","article-title":"The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study","volume":"61","author":"Tsuzaki","year":"2012","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10284150400009998","article-title":"Adiponectin: novelties in metabolism and hormonal regulation","volume":"7","author":"Duntas","year":"2004","journal-title":"Nutr Neurosci"},{"issue":"2","key":"10.1016\/j.metabol.2012.04.013_bb0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/en.2003-1140","article-title":"Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice","volume":"145","author":"Xu","year":"2004","journal-title":"Endocrinology"},{"issue":"6748","key":"10.1016\/j.metabol.2012.04.013_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0155","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz","year":"2004","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0160","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/diabetes.50.6.1440","article-title":"Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes","volume":"50","author":"Ebihara","year":"2001","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0165","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.metabol.2010.03.016","article-title":"Leptin increases skeletal muscle lipoprotein lipase and postprandial lipid metabolism in mice","volume":"60","author":"Donahoo","year":"2011","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0170","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.metabol.2012.04.013_bb0175","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2011.04.008","article-title":"Effects of leptin and adiponectin on pancreatic beta-cell function","volume":"60","author":"Lee","year":"2011","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0180","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.metabol.2010.07.023","article-title":"Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study","volume":"60","author":"Sekhar","year":"2011","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"issue":"9407","key":"10.1016\/j.metabol.2012.04.013_bb0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy\u2013a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"issue":"12","key":"10.1016\/j.metabol.2012.04.013_bb0200","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/518005","article-title":"A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy","volume":"195","author":"Cavalcanti","year":"2007","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.metabol.2012.04.013_bb0205","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/427697","article-title":"Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 \u00d7 2 factorial, randomized, double-blinded, placebo-controlled trial","volume":"40","author":"Gavrila","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0215","doi-asserted-by":"crossref","first-page":"E567","DOI":"10.1152\/ajpendo.00315.2011","article-title":"Leptin in human physiology and pathophysiology","volume":"301","author":"Mantzoros","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.metabol.2012.04.013_bb0220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2012.04.013_bb0225","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0230","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM200408053510623","article-title":"Long-term leptin-replacement therapy for lipoatrophic diabetes","volume":"351","author":"Ebihara","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0235","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.metabol.2012.04.013_bb0240","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","article-title":"Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0245","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2012.04.013_bb0250","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1210\/jc.2009-0340","article-title":"Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?","volume":"94","author":"Mantzoros","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2012.04.013_bb0255","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.metabol.2010.10.002","article-title":"Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2012.04.013_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2012.03.013","article-title":"Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome","author":"Sekhar","year":"2012","journal-title":"Metabolism"},{"issue":"8934","key":"10.1016\/j.metabol.2012.04.013_bb0265","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.metabol.2012.04.013_bb0270","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2165\/00003088-200241140-00004","article-title":"Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection","volume":"41","author":"Fichtenbaum","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.metabol.2012.04.013_bb0275","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.metabol.2011.05.022","article-title":"Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future","volume":"60","author":"Tsiodras","year":"2011","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.metabol.2012.04.013_bb0280","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.metabol.2011.03.015","article-title":"Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients","volume":"60","author":"Daali","year":"2011","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0285","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1592\/phco.28.7.913","article-title":"Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy","volume":"28","author":"Rahman","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.metabol.2012.04.013_bb0290","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000441-200406000-00003","article-title":"Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy","volume":"327","author":"Rao","year":"2004","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.metabol.2012.04.013_bb0295","doi-asserted-by":"crossref","unstructured":"Ginsberg, H.N., Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. The American journal of cardiology, 2001. 87(10): p. 1174--80; A4.","DOI":"10.1016\/S0002-9149(01)01489-8"},{"issue":"23","key":"10.1016\/j.metabol.2012.04.013_bb0300","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV","volume":"357","author":"Falutz","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.metabol.2012.04.013_bb0305","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","volume":"95","author":"Falutz","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0310","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.metabol.2012.04.013_bb0315","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAI.0b013e3181a9992c","article-title":"Association of C-reactive protein and HIV infection with acute myocardial infarction","volume":"51","author":"Triant","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.metabol.2012.04.013_bb0320","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/QAI.0b013e3181f4b752","article-title":"Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system","volume":"55","author":"Triant","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2012.04.013_bb0325","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11904-010-0047-3","article-title":"Abacavir and cardiovascular risk: reviewing the evidence","volume":"7","author":"Costagliola","year":"2010","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:56:42Z","timestamp":1758427002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049512001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0026049512001618"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2012.04.013","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.03.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}